Physician profile
Lenito J Sinay
NPI 1225047632
$7,851.17
in general payments reported to CMS, 2019-2025
33 companies · $1,179 in 2025
The $1,179 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $518 · 2020: $1,057 · 2021: $1,317 · 2022: $962 · 2023: $1,069 · 2024: $1,748 · 2025: $1,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,996.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,160.56 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,036.19 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $947.63 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $586.14 | 2019-2025 | Jardiance, Ofev |
| Lilly USA, LLC | $521.11 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $464.69 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $447.71 | 2022-2025 | |
| Amgen INC. | $399.62 | 2020-2024 | Repatha, Otezla, Evenity |
| Abbvie INC. | $334.29 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $295.51 | 2019-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Astellas Pharma US INC | $210.55 | 2019-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $196.32 | 2021-2024 | Xarelto |
| Amarin Pharma, INC. | $190.62 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $136.17 | 2019-2023 | |
| Dexcom, INC. | $115.13 | 2024-2025 | Dexcom G6 Transmitter |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $105.81 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Esperion Therapeutics, INC. | $104.06 | 2020-2024 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $86.67 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $75.28 | 2023-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $69.14 | 2023-2024 | |
| Exact Sciences Corporation | $50.93 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $44.21 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $44.03 | 2021-2023 | Eliquis |
| Abbott Laboratories | $37.15 | 2025 | Freestyle Libre |
| Allergan, INC. | $31.87 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $30.72 | 2019-2023 | Livalo |
| Zyla Life Sciences, INC. | $24.92 | 2019-2020 | |
| Inspire Medical Systems, INC. | $21.38 | 2025 | Inspire |
| Edwards Lifesciences Corporation | $20.54 | 2023 | |
| Alexion Pharmaceuticals, INC. | $17.05 | 2022 | |
| Alfasigma USA, INC. | $16.72 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.85 | 2025 | Rexulti |
| Dynavax Technologies Corporation | $13.60 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lenito Sinay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.